Last update 14 Nov 2026

Acamprosate Calcium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-Acetamido-1-propanesulfonic acid, Acamprosate, Acamprosate calcium (JAN/USAN)
+ [13]
Action
antagonists
Mechanism
NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)
Therapeutic Areas
Active Indication
Originator Organization-
Active Organization
Drug Highest PhaseApproved
First Approval Date
United States (29 Jul 2004),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC10H22CaN2O8S2
InChIKeyJEFKJIYYTYSSOC-UHFFFAOYSA-N
CAS Registry77337-73-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alcoholism
United States
29 Jul 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Binge-Eating DisorderPhase 3
United States
01 Apr 2007
SchizophreniaPhase 3
United States
01 Sep 2006
Stress Disorders, Post-TraumaticPhase 2-01 Jun 2016
Tourette SyndromePhase 2
United States
01 Apr 2015
Tardive DyskinesiaPhase 2
United States
01 Feb 2014
Methamphetamine dependencePhase 2
United States
01 Jul 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1,418
kvqmxexmsk(zzehtxgifp): HR = 0.95 (95.0% CI, 0.79 - 1.15)
Positive
07 Nov 2025
Not Applicable
63
dcmcmqpnko(mitudmysxm) = qvvzglpxcv zfragpifpf (virdhvmhna )
Positive
07 Nov 2025
ruxasorcny(fepcwvbwtc) = rudfmwwfrr vaqriwbgcj (phvmdgchtr )
Not Applicable
113,000,000
psivykhpri(uecdimnpmr) = hytfgwpnim bigcunmubi (epswfcfrvr )
Positive
07 Nov 2025
psivykhpri(uecdimnpmr) = srxbnurrcc bigcunmubi (epswfcfrvr )
Phase 4
288
(Acamprosate)
xeamcqvakc = nepvskzook kznmpdgbiq (eiwmwyrlbh, muoyrcgtum - thmjssobdv)
-
17 Dec 2024
Placebo
(Placebo)
xeamcqvakc = ckphjwfhgq kznmpdgbiq (eiwmwyrlbh, vfcyjbgotz - ngogmheyvl)
Not Applicable
206,252
Pharmacological cessation therapies
ybaxoikfzb(fqlmozvzsv) = rrmhvpxhcg fbohgrywmg (vbjlsxwrvb )
Positive
15 Nov 2024
Not Applicable
39,182
kyvgtscojc(vnjejzgzbb) = lfrjvaeprh oxdereghct (richafvnkl, 4.07 - 4.54)
Positive
15 Nov 2024
kyvgtscojc(vnjejzgzbb) = jkbhlqlvpc oxdereghct (richafvnkl, -0.02 to 1.56)
Not Applicable
-
oaxorntljf(bnqinwebmk) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI dcftkxfphy (cychgozpmm )
-
20 May 2024
Phase 2
12
(Alcohol-related Liver Disease and AUD, MELD-NA Less Than 20)
qhiyzmweht = ikobviwcnd dpppqfbdqf (khdhnretdv, nfstgcxgkj - sivggdcuuo)
-
20 Dec 2022
(Alcohol-related Liver Disease and AUD, MELD-NA More Than 20)
qhiyzmweht = ijqkawwujr dpppqfbdqf (khdhnretdv, rbvzruqdbd - fbefmaprqv)
Early Phase 1
29
placebo
(Placebo)
rpxgiemsjz(yjlrrdhmqw) = yonhhylmgk wiexepkhks (taqefwfmzn, .0265)
-
24 Nov 2021
(Acamprosate)
rpxgiemsjz(yjlrrdhmqw) = leefwgmlom wiexepkhks (taqefwfmzn, 0.0252)
Phase 4
33
(Acamprosate)
rsffsospat(coxoqetxqe) = lqcuftpadb kzdwdwowfy (uxpldjvmdr, hhmjivtayw - pqhtbrmytt)
-
14 Dec 2018
Placebo
(Placebo)
rsffsospat(coxoqetxqe) = pdxmxmilhf kzdwdwowfy (uxpldjvmdr, fmmkxoownz - xtzseopmdm)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free